<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0420</journal-id>
<journal-title><![CDATA[Revista Uruguaya de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Urug.Cardiol.]]></abbrev-journal-title>
<issn>1688-0420</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Uruguaya de Cardiología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-04202019000100060</article-id>
<article-id pub-id-type="doi">10.29277/cardio.34.1.7</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Efectividad y seguridad de eplerenona en la miocardiopatía isquémica con fracción de eyección reducida. Experiencia clínica preliminar en una unidad multidisciplinaria]]></article-title>
<article-title xml:lang="en"><![CDATA[Effectiveness and safety of eplerenone in ischemic cardiomyopathy with reduced ejection fraction. Clinical preliminary experience in a multidisciplinary unit]]></article-title>
<article-title xml:lang="pt"><![CDATA[Eficácia e segurança da eplerenona na cardiomiopatia isquêmica com fração de ejeção reduzida. Experiência clínica preliminar em uma unidade multidisciplinar]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramos]]></surname>
<given-names><![CDATA[Camila]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Parma]]></surname>
<given-names><![CDATA[Gabriel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silvera]]></surname>
<given-names><![CDATA[Gabriela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ormaechea]]></surname>
<given-names><![CDATA[Gabriela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tamosiunas]]></surname>
<given-names><![CDATA[Gustavo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[Pablo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Florio]]></surname>
<given-names><![CDATA[Lucía]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[UMIC]]></surname>
<given-names><![CDATA[Grupo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de la República Hospital de Clínicas Unidad Multidisciplinaria de Insuficiencia Cardíaca. Clínica Médica A; Cátedra de Cardiología]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de la República Hospital de Clínicas Departamento de Farmacología y Terapéutica]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2019</year>
</pub-date>
<volume>34</volume>
<numero>1</numero>
<fpage>60</fpage>
<lpage>84</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-04202019000100060&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-04202019000100060&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-04202019000100060&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  los antagonistas del receptor de mineralocorticoides han demostrado ser beneficiosos en pacientes con insuficiencia cardíaca y fracción de eyección reducida (ICFEr) sintomática. Sin embargo, se dispone de escasa evidencia respecto a sus efectos hemodinámicos y no existen reportes locorregionales sobre su uso en la práctica clínica. En esta experiencia inicial analizamos el perfil de efectividad y seguridad de eplerenona a mediano plazo en portadores de miocardiopatía isquémica con ICFEr.  Material y métodos:  se realizó un estudio prospectivo, abierto, en una muestra por conveniencia de pacientes asistidos en una unidad de insuficiencia cardíaca con antecedente de infarto agudo de miocardio (IAM) y fracción de eyección del ventrículo izquierdo (FEVI) &lt;40%. Eplerenona se prescribió en dosis ajustadas al índice de filtrado glomerular, asociada a la terapia crónica usual, basada en las guías de práctica clínica. Cada paciente ofició de su propio control a los seis meses, con medidas seriadas en las variables clínicas, de laboratorio, estructurales, hemodinámicas y en tests de calidad de vida (cuestionario de Minnesota) y adherencia (escala de Morisky-Green).  Resultados:  se incluyeron 26 pacientes, 73% hombres, con una edad de 66,3 ± 9,7 años. No se observaron cambios en las variables clínicas durante el seguimiento a mediano plazo. Se observó un aumento de la FEVI (29,4% ± 7,2% a 32,0% ± 7,4%, p = 0,02) y en el gasto cardíaco (4,1 ± 1,1 l/min a 4,9 ± 1,0 l/min, p = 0,0007) y una disminución de la resistencia vascular sistémica (1669,8 ± 544,2 dinas.s/cm5 a 1.248,4 ± 350,6 dinas.s/cm5, p = 0,01). Aunque el uso de eplerenona se asoció con un aumento en los niveles de potasio y con una disminución en la tasa de filtración glomerular, no hubo hospitalizaciones ni muertes a los seis meses. Además, la eplerenona se asoció con una mejoría en la calidad de vida (puntaje de Minnesota: 17,5 a 10,0 puntos, p = 0,02) y una buena adherencia al tratamiento.  Conclusión:  el uso de eplerenona se asoció con una mejoría del perfil hemodinámico y de la calidad de vida, buena seguridad y adecuada adherencia al tratamiento a mediano plazo en pacientes con ICFEr de etiología isquémica. Mediante series mayores y un seguimiento más prolongado deben compararse los efectos hemodinámicos en subpoblaciones de pacientes con ICFEr de diferentes etiologías.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Summary:  Introduction:  mineralocorticoid receptor antagonists have been shown to be beneficial in patients with symptomatic heart failure and reduced ejection fraction. However, little evidence is available regarding its hemodynamic effects and, at the same time, there are no loco-regional reports on its use in real clinical practice. Our preliminary experience analyzed the medium term effectiveness and safety profile of eplerenone in patients with ischemic cardiomyopathy and reduced ejection fraction.  Material and methods:  a prospective open study was performed in a convenience sample of patients treated in a heart failure unit with acute myocardial infarction and left ventricular ejection fraction &lt;40%. Eplerenone was prescribed in doses adjusted to the glomerular filtration rate combined with the usual chronic therapy agents based on clinical practice guidelines. Each patient performed as his own control at 6 months with serial measurements in clinical, laboratory, structural and hemodynamic variables and in the quality of life and adherence tests (Minnesota questionnaire and Morisky-Green scale).  Results:  we included 26 patients, 73% men, with an age of 66.3 ± 9.7 years. No changes were observed in the clinical variables during midterm follow-up. An increase of left ventricular ejection fraction (29.4% ± 7.2% to 32.0% ± 7.4%, p = 0.02) and cardiac output (4.1 ± 1.1 l/min to 4.9 ± 1.0 l/min, p = 0.0007) and a decrease in systemic vascular resistance (1669.8 ± 544.2 dynes.s/cm5 to 1248.4 ± 350.6 dynes.s/cm5, p = 0.01) were observed. Although the use of eplerenone was associated with an increase in potassium levels and a decrease in the glomerular filtration rate, there were no hospitalizations or deaths at 6 months. In addition, eplerenone was associated with an improvement in quality of life (Minnesota score: 17.5 to 10.0 points, p = 0.02) and good adherence to treatment.  Conclusion:  the use of eplerenone was associated with an improvement in the hemodynamic profile and quality of life, good safety and adequate adherence to treatment in the midterm in patients with ischemic heart failure and reduced ejection fraction. Large series evaluated through longer follow-up should compare hemodynamic effects among subpopulations of patients with heart failure of different etiologies.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  antagonistas dos receptores mineralocorticóides têm demonstrado ser benéficos em pacientes com insuficiência cardíaca sintomática e fração de ejeção reduzida. No entanto, poucas evidências estão disponíveis em relação aos seus efeitos hemodinâmicos e não há relatos locorregionais sobre seu uso na prática clínica. Nesta experiência inicial analisamos o perfil de eficácia e segurança da eplerenona a médio prazo em portadores de cardiomiopatia isquêmica com fração de ejeção reduzida.  Material e métodos: um estudo aberto prospectivo foi realizado em uma amostra de conveniência de pacientes atendidos em uma unidade de insuficiência cardíaca, com história de infarto agudo do miocárdio e fração de ejeção &lt;40%. A eplerenona foi prescrita na taxa de filtração glomerular ajustada, combinada com os agentes de terapia crônica usuais baseados nas diretrizes de prática clínica. Cada paciente realizou seu controle aos 6 meses com medidas seriadas em variáveis clínicas, laboratoriais, estruturais, hemodinâmicas, e em testes de qualidade de vida (Questionário de Minnesota) e aderência (escala Morisky-Green).  Resultados: foram incluídos 26 pacientes, 73% homens, com idade de 66,3 ± 9,7 anos. Não foram observadas alterações nas variáveis clínicas durante o seguimento de médio prazo. Observou-se aumento na fração de ejeção (29,4% ± 7,2% a 32,0% ± 7,4%, p = 0,02) e no débito cardíaco (4,1 ± 1,1 l / min na 4,9 ± 1,0 l / min, p = 0,0007) e uma diminuição na resistência vascular sistêmica (1669,8 ± 544,2 dynes.s/cm5 a 1248,4 ± 350,6 dynes.s/cm5, p = 0,01). Embora o uso de eplerenona tenha sido associado a um aumento nos níveis de potássio e uma diminuição na taxa de filtração glomerular, não houve hospitalizações ou mortes aos 6 meses. Além disso, a eplerenona foi associada a uma melhora na qualidade de vida (escore de Minnesota: 17,5 a 10,0 pontos, p = 0,02) e boa adesão ao tratamento.  Conclusão:  o uso de eplerenona foi associado com melhor perfil hemodinâmico e qualidade de vida, boas condições de segurança e aderência adequada para o tratamento em médio prazo de pacientes com insuficiência cardíaca com fração de ejeção reduzida de etiologia isquêmica. Para séries maiores e acompanhamento mais prolongado, deve-se comparar os efeitos hemodinâmicos em subpopulações tendo insuficiência cardíaca e fração de ejeção reduzida de diferentes etiologias.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Insuficiencia Cardíaca]]></kwd>
<kwd lng="es"><![CDATA[Infarto]]></kwd>
<kwd lng="es"><![CDATA[Efectividad]]></kwd>
<kwd lng="es"><![CDATA[Seguridad]]></kwd>
<kwd lng="en"><![CDATA[Heart Failure]]></kwd>
<kwd lng="en"><![CDATA[Infarction]]></kwd>
<kwd lng="en"><![CDATA[Effectiveness]]></kwd>
<kwd lng="en"><![CDATA[Safety]]></kwd>
<kwd lng="pt"><![CDATA[Insuficiência cardíaca]]></kwd>
<kwd lng="pt"><![CDATA[Infarto]]></kwd>
<kwd lng="pt"><![CDATA[Efetividade]]></kwd>
<kwd lng="pt"><![CDATA[Segurança]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mosterd]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hoes]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical epidemiology of heart failure]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2007</year>
<volume>93</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1137-46</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mann]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Bristow]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms and models in heart failure the biomechanical model and beyond]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2005</year>
<volume>111</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2837-49</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ponikowski]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Voors]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Anker]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bueno]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Cleland]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Coats]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC]]></article-title>
<source><![CDATA[Eur Hear J]]></source>
<year>2016</year>
<volume>37</volume>
<numero>27</numero>
<issue>27</issue>
<page-range>2129-200</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yancy]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Jessup]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bozkurt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Butler]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Casey]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Drazner]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2013 ACCF/AHA guideline for the management of heart failure a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2013</year>
<volume>128</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>e240-327</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pitt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Zannad]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Remme]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cody]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Castaigne]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Perez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1999</year>
<volume>341</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>709-17</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pitt]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Remme]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zannad]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Neaton]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Roniker]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2003</year>
<volume>348</volume>
<numero>14</numero>
<issue>14</issue>
<page-range>1309-21</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zannad]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[McMurray]]></surname>
<given-names><![CDATA[JJV]]></given-names>
</name>
<name>
<surname><![CDATA[Krum]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[van Veldhuisen]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Swedberg]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eplerenone in patients with systolic heart failure and mild symptoms]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>364</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-21</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parthasarathy]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
<name>
<surname><![CDATA[Macdonald]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Review Aldosterone antagonists]]></article-title>
<source><![CDATA[Br J Diabetes Vasc Dis]]></source>
<year>2008</year>
<volume>8</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>215-9</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="book">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[Perspectivas políticas de la OMS sobre medicamentos. Promoción del uso racional de medicamentos: componentes centrales (Internet)]]></source>
<year>2002</year>
<publisher-loc><![CDATA[Ginebra ]]></publisher-loc>
<publisher-name><![CDATA[OMS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alvarez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ormaechea]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ricca]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Unidad de Insuficiencia Cardíaca Breve reseña del tema y evaluación de gestión de la primera unidad de insuficiencia cardíaca pública del Uruguay (grupo UMIC)]]></article-title>
<source><![CDATA[Archivos de Medicina Interna]]></source>
<year>2009</year>
<volume>31</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>11-7</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garin]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Soriano]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ribera]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pont]]></surname>
<given-names><![CDATA[À]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validación de la versión española del Minnesota Living with Heart Failure Questionnaire]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2008</year>
<volume>61</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>251-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shalansky]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Ignaszewski]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Self-reported Morisky Score for Identifying Nonadherence with Cardiovascular Medications]]></article-title>
<source><![CDATA[Ann Pharmacother]]></source>
<year>2004</year>
<volume>38</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1363-8</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Florio]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Vignolo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Centurión]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Manfredi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cuña]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factibilidad de la valoración hemodinámica ecocardiográfica no invasiva en la insuficiencia cardíaca crónica]]></article-title>
<source><![CDATA[Rev Urug Cardiol]]></source>
<year>2006</year>
<volume>21</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>117-23</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Florio]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Vignolo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Centurión]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pouso]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cálculo de resistencia vascular sistémica por ecocardiografía en la insuficiencia cardíaca crónica una herramienta para optimizar la dosis de IECA y ARA II]]></article-title>
<source><![CDATA[Insuficiencia Cardíaca]]></source>
<year>2006</year>
<volume>7</volume>
<page-range>2-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Traversi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-invasive evaluation of the hemodynamic profile in patients with heart failure estimation of cardiac output]]></article-title>
<source><![CDATA[Ital Heart J Suppl]]></source>
<year>2000</year>
<volume>1</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1334-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohn]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Shabetai]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Loeb]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Tristani]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rector]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure The V-HeFT VA Cooperative Studies Group]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>1993</year>
<volume>87</volume>
<numero>^s6</numero>
<issue>^s6</issue>
<supplement>6</supplement>
<page-range>SI5-16</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Morita]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mishima]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sharov]]></surname>
<given-names><![CDATA[VG]]></given-names>
</name>
<name>
<surname><![CDATA[Todor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tanhehco]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2002</year>
<volume>106</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>2967-72</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gomez-Sanchez]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Gomez-Sanchez]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Central regulation of blood pressure by the mineralocorticoid receptor]]></article-title>
<source><![CDATA[Mol Cell Endocrinol]]></source>
<year>2012</year>
<volume>350</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>289-98</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beygui]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Collet J-P]]></surname>
</name>
<name>
<surname><![CDATA[Benoliel J-J]]></surname>
</name>
<name>
<surname><![CDATA[Vignolles]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Dumaine]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Barthelemy]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2006</year>
<volume>114</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2604-10</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palmer]]></surname>
<given-names><![CDATA[BR]]></given-names>
</name>
<name>
<surname><![CDATA[Pilbrow]]></surname>
<given-names><![CDATA[AP]]></given-names>
</name>
<name>
<surname><![CDATA[Frampton]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Yandle]]></surname>
<given-names><![CDATA[TG]]></given-names>
</name>
<name>
<surname><![CDATA[Skelton]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Nicholls]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2008</year>
<volume>29</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>2489-96</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beygui]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Montalescot]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Vicaut]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rouanet]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Van Belle]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Baulac]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aldosterone and long-term outcome after myocardial infarction A substudy of the french nationwide Observatoire sur la Prise en charge hospitalière, l'Evolution à un an et les caRactéristiques de patients présentant un infArctus du myocarde avec ou sans onde Q (OPERA) study]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>2009</year>
<volume>157</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>680-7</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Deng]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Du]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[She]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>2013</year>
<volume>75</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1202-12</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Phelan]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Thavendiranathan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Collier]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Marwick]]></surname>
<given-names><![CDATA[TH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class a meta-analysis of randomised controlled trials]]></article-title>
<source><![CDATA[Heart]]></source>
<year>2012</year>
<volume>98</volume>
<numero>23</numero>
<issue>23</issue>
<page-range>1693-700</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Soto]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Nallamothu]]></surname>
<given-names><![CDATA[BK]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Weintraub]]></surname>
<given-names><![CDATA[WS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patient health status and costs in heart failure insights from the Eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS)]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2009</year>
<volume>119</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>398-407</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spertus]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Tooley]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Poston]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mahoney]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Deedwania]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expanding the outcomes in clinical trials of heart failure the quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal Efficacy and SUrvival Study)]]></article-title>
<source><![CDATA[Am Heart J]]></source>
<year>2002</year>
<volume>143</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>636-42</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Juurlink]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
<name>
<surname><![CDATA[Mamdani]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Kopp]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Austin]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Laupacis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rates of hyperkalemia after publication of the randomized aldactone evaluation study]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2004</year>
<volume>351</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>543-51</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Unverzagt]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mittmann]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Samos F-A]]></surname>
</name>
<name>
<surname><![CDATA[Unverzagt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Prondzinsky]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improving Treatment Adherence in Heart Failure]]></article-title>
<source><![CDATA[Dtsch Arztebl Int]]></source>
<year>2016</year>
<volume>113</volume>
<numero>25</numero>
<issue>25</issue>
<page-range>423-30</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oosterom-Calo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[van Ballegooijen]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Terwee]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[te Velde]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Brouwer]]></surname>
<given-names><![CDATA[IA]]></given-names>
</name>
<name>
<surname><![CDATA[Jaarsma]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Determinants of adherence to heart failure medication a systematic literature review]]></article-title>
<source><![CDATA[Heart Fail Rev]]></source>
<year>2013</year>
<volume>18</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>409-27</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
